The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In another milestone, Eli Lilly's weight-loss medication, Zepbound, received FDA approval, marking it as the first drug to specifically tackle moderate to severe obstructive sleep apnea in obese ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

And here’s what else you need to know to Start Your Week Smart . Your day is busy. 5 Things is your one-stop shop for the ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept. 23 in Children. In a new analysis of national data, researchers at the ...

Obstructive sleep apnea (OSA) and the metabolic syndrome have a strong association with each other owing to their common feature of obesity, but an association independent of obesity has been ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo ...